Palvella Therapeutics (PVLA) News Today $22.88 -0.35 (-1.51%) As of 01:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock PVLA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cresset Asset Management LLC Purchases New Holdings in Palvella Therapeutics (NASDAQ:PVLA)Cresset Asset Management LLC purchased a new stake in Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 20,911 shares of the company's stock, valued at approximately $251,000. CMay 20 at 4:09 AM | marketbeat.comSuvretta Capital Management LLC Takes $8.57 Million Position in Palvella Therapeutics (NASDAQ:PVLA)Suvretta Capital Management LLC bought a new stake in Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 714,463 shares of the company's stock, valued at apprMay 19 at 7:41 AM | marketbeat.comCanaccord Genuity Group Cuts Palvella Therapeutics (NASDAQ:PVLA) Price Target to $52.00May 19 at 3:03 AM | americanbankingnews.comBrokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $44.43May 19 at 2:05 AM | americanbankingnews.comPromising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market PositionMay 16, 2025 | tipranks.comPalvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...May 16, 2025 | finance.yahoo.comPalvella Therapeutics (NASDAQ:PVLA) Given Average Recommendation of "Buy" by AnalystsPalvella Therapeutics (NASDAQ:PVLA - Get Free Report) has been given a consensus rating of "Buy" by the eight ratings firms that are presently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. TheMay 16, 2025 | marketbeat.comQ1 2025 Palvella Therapeutics Inc Earnings Call TranscriptMay 16, 2025 | gurufocus.comPalvella Therapeutics Inc.: Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finanznachrichten.dePalvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | globenewswire.comPalvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on ThursdayMay 14, 2025 | americanbankingnews.comPalvella Therapeutics Rings the Opening BellMay 13, 2025 | nasdaq.comPalvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor CallMay 12, 2025 | msn.com71,452 Shares in Palvella Therapeutics (NASDAQ:PVLA) Bought by DAFNA Capital Management LLCDAFNA Capital Management LLC purchased a new stake in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 71,452 shares of the company's stocMay 10, 2025 | marketbeat.comPalvella Therapeutics to Ring Nasdaq Opening BellMay 9, 2025 | msn.comPalvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025May 8, 2025 | globenewswire.comRenaissance Technologies LLC Buys New Holdings in Palvella Therapeutics (NASDAQ:PVLA)Renaissance Technologies LLC purchased a new position in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,371 shares of the compMay 8, 2025 | marketbeat.comBVF Inc. IL Purchases New Stake in Palvella Therapeutics (NASDAQ:PVLA)BVF Inc. IL purchased a new position in Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 696,555 shares of the company's stock, valued at approximaMay 6, 2025 | marketbeat.comGeode Capital Management LLC Invests $171,000 in Palvella Therapeutics (NASDAQ:PVLA)Geode Capital Management LLC purchased a new stake in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 14,270 shares of the company's stock, valued at approximately $171,000. Geode Capital MaMay 6, 2025 | marketbeat.comPalvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025May 5, 2025 | globenewswire.comAdams Street Partners LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)Adams Street Partners LLC bought a new position in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 409,666 shares of the company's stock, valued atMay 4, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Palvella Therapeutics (NASDAQ:PVLA)HC Wainwright reissued a "buy" rating and issued a $38.00 price target on shares of Palvella Therapeutics in a report on Wednesday.May 2, 2025 | marketbeat.comSamsara BioCapital LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)Samsara BioCapital LLC purchased a new stake in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 679,486 shares of the company's stock, valued at approximately $8,154,000.May 2, 2025 | marketbeat.comNantahala Capital Management LLC Buys Shares of 250,062 Palvella Therapeutics (NASDAQ:PVLA)Nantahala Capital Management LLC acquired a new position in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 250,062 shares of the company's stock, valued atApril 30, 2025 | marketbeat.comPalvella Therapeutics to Present Key Findings on Lymphatic Malformations at Dermatology ConferenceApril 28, 2025 | msn.comOne Palvella Therapeutics Insider Raised Their Stake In The Previous YearApril 26, 2025 | finance.yahoo.comBlue Owl Capital Holdings LP Takes $3 Million Position in Palvella Therapeutics (NASDAQ:PVLA)Blue Owl Capital Holdings LP purchased a new stake in Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 250,062 shares of the company's stock, valued at approximately $3,001,000. PalvellApril 26, 2025 | marketbeat.comPalvella Therapeutics secures new patent for rare skin disease gelApril 24, 2025 | uk.investing.comPalvella Therapeutics Secures New U.S. Patent for QTORIN RapamycinApril 23, 2025 | msn.comPalvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative DermatologyApril 23, 2025 | globenewswire.comPalvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic MalformationsApril 22, 2025 | globenewswire.comWhat is Chardan Capital's Estimate for PVLA FY2025 Earnings?Palvella Therapeutics (NASDAQ:PVLA - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Palvella Therapeutics in a report released on Wednesday, April 9th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings perApril 15, 2025 | marketbeat.comPalvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic DisorderApril 12, 2025 | msn.comPalvella Therapeutics announces data on QTORIN rapamycinApril 11, 2025 | markets.businessinsider.comPalvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Chardan CapitalChardan Capital initiated coverage on shares of Palvella Therapeutics in a report on Wednesday. They issued a "buy" rating and a $50.00 target price on the stock.April 11, 2025 | marketbeat.comPalvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric DermatologyApril 11, 2025 | globenewswire.comGeorge M. Jenkins Purchases 2,500 Shares of Palvella Therapeutics (NASDAQ:PVLA) StockApril 11, 2025 | insidertrades.comDirector Makes Bold Move with Major Stock Purchase in Palvella Therapeutics!April 10, 2025 | tipranks.comPalvella Therapeutics initiated with a Buy at ChardanApril 9, 2025 | markets.businessinsider.comChardan Capital Initiates Coverage of Palvella Therapeutics (PVLA) with Buy RecommendationApril 9, 2025 | msn.comADAR1 Capital Management LLC Invests $1.74 Million in Palvella Therapeutics (NASDAQ:PVLA)ADAR1 Capital Management LLC bought a new stake in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 144,641 shares of the company's stock, valued at approximately $1,7April 9, 2025 | marketbeat.comQ1 EPS Forecast for Palvella Therapeutics Lowered by AnalystPalvella Therapeutics (NASDAQ:PVLA - Free Report) - Equities researchers at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a report issued on Tuesday, April 1st. HC Wainwright analyst A. Fein now anticipates that the company will post earApril 6, 2025 | marketbeat.comPalvella CEO to Present at Healthcare Innovation ConferenceApril 6, 2025 | msn.comPalvella Therapeutics to Present at the Jones Healthcare and Technology Innovation ConferenceApril 4, 2025 | gurufocus.comPalvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology CongressApril 2, 2025 | msn.comPalvella Therapeutics price target raised to $53 from $39 at CanaccordApril 2, 2025 | markets.businessinsider.comPalvella Therapeutics (PVLA) Receives a Buy from ScotiabankApril 2, 2025 | markets.businessinsider.comPalvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease PipelineApril 2, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $38.00 target price on shares of Palvella Therapeutics in a report on Tuesday.April 2, 2025 | marketbeat.comPalvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric DermatologyApril 2, 2025 | globenewswire.com Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address PVLA Media Mentions By Week PVLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PVLA News Sentiment▼0.640.65▲Average Medical News Sentiment PVLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PVLA Articles This Week▼134▲PVLA Articles Average Week Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PAHC News Today COLL News Today RCUS News Today SYRE News Today PHVS News Today AVDL News Today NTLA News Today CMRX News Today CDMO News Today SNDX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PVLA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PVLA Stock Free PVLA Stock Alerts